Tom Foltynie
Overview
Explore the profile of Tom Foltynie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
2670
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vijiaratnam N, Girges C, Auld G, McComish R, King A, Skene S, et al.
Lancet
. 2025 Feb;
405(10479):627-636.
PMID: 39919773
Background: GLP-1 receptor agonists have neurotrophic properties in in-vitro and in-vivo models of Parkinson's disease and results of epidemiological studies and small randomised trials have suggested possible benefits for risk...
2.
Foltynie T, Zrinzo L
Handb Clin Neurol
. 2024 Sep;
205:101-110.
PMID: 39341647
While there are a diverse number of indications for the potential use of cell and gene therapies in people, many of the medical conditions being treated need to consider some...
3.
Fabbri M, Rascol O, Foltynie T, Carroll C, Postuma R, Porcher R, et al.
Mov Disord
. 2024 Jun;
39(9):1468-1477.
PMID: 38925541
Traditional drug development in Parkinson's disease (PD) faces significant challenges because of its protracted timeline and high costs. In response, innovative master protocols are emerging and designed to address multiple...
4.
Dobreva I, Thomas J, Marr A, OConnell R, Roche M, Hannaway N, et al.
Mov Disord Clin Pract
. 2024 May;
11(7):814-824.
PMID: 38696333
Background: People with Parkinson's disease (PD) have an increased risk of dementia, yet patients and clinicians frequently avoid talking about it due to associated stigma, and the perception that "nothing...
5.
Foltynie T, Bruno V, Fox S, Kuhn A, Lindop F, Lees A
Lancet
. 2024 Jan;
403(10423):305-324.
PMID: 38245250
Although dopamine replacement therapy remains a core component of Parkinson's disease treatment, the onset of motor fluctuations and dyskinetic movements might require a range of medical and surgical approaches from...
6.
Martinez-Carrasco A, Real R, Lawton M, Iwaki H, Tan M, Wu L, et al.
NPJ Parkinsons Dis
. 2023 Aug;
9(1):128.
PMID: 37652906
The genetic basis of levodopa-induced-dyskinesia (LiD) is poorly understood, and there have been few well-powered genome-wide studies. We performed a genome-wide survival meta-analyses to study the effect of genetic variation...
7.
Martinez-Carrasco A, Real R, Lawton M, Iwaki H, Tan M, Wu L, et al.
medRxiv
. 2023 Jul;
PMID: 37425912
Importance: Forty percent of Parkinson's disease patients develop levodopa-induced-dyskinesia (LiD) within 4 years of starting levodopa. The genetic basis of LiD remains poorly understood, and there have been few well...
8.
Eraifej J, Cabral J, Fernandes H, Kahan J, He S, Mancini L, et al.
Netw Neurosci
. 2023 Jul;
7(2):478-495.
PMID: 37397890
Beyond the established effects of subthalamic nucleus deep brain stimulation (STN-DBS) in reducing motor symptoms in Parkinson's disease, recent evidence has highlighted the effect on non-motor symptoms. However, the impact...
9.
10.
Zacharia A, Kaski D, Bouthour W, Dayal V, Bereau M, Mahlknecht P, et al.
NPJ Parkinsons Dis
. 2023 Mar;
9(1):50.
PMID: 37002261
Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an effective treatment for Parkinson's disease (PD). Varying the frequency DBS has differential effects on axial and distal limb functions,...